Product Description
Celgosivir is a 6-0-butanoyl ester derivative of castanospermine, a compound derived from the Australian chestnut with activity against hepatitis C virus. Celgosivir rapidly converts to castanospermine in the body, where it is a potent inhibitor of alpha-glucosidase I, a host enzyme required for viral assembly, release, and infectivity. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Celgosivir)
Mechanisms of Action: GAA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioWest
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatitis C, Chronic|Hepatitis A|Dengue|HIV Infections
Phase 1: HIV Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Cel01 | P2 |
Withdrawn |
Dengue |
2019-08-08 |
|
| CELADEN | P2 |
Completed |
Dengue |
2013-03-01 |
|
| HCV-06-001 | P2 |
Unknown status |
Hepatitis A|Hepatitis C, Chronic |
2008-12-01 |
|
| HCV-04-001 | P2 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
None |